2 reasons I’m buying at the current AstraZeneca share price

With strong historical results and a number of drugs in development, does the AstraZeneca share price now make the stock a glaring buy for me?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Key points

  • Between the 2017 and 2021 calendar years, total revenue grew from $22bn to $37bn
  • The firm completed a takeover of Alexion Pharmaceuticals in July 2021
  • Lynparza, a breast cancer treatment, gained full approval in the US on 14 March 2022 

AstraZeneca (LSE:AZN) shot to front page headlines when it developed one of the first Covid-19 vaccines. As a pharmaceutical and biotechnology giant, it operates three segments, including oncology, cardiovascular, and respiratory. Unsurprisingly, the AstraZeneca share price has performed well in recent times. It’s up 34.5% in the past year and currently trades at 9,434p. As the pandemic subsides, however, I want to look deeper into this company to see if I should add it to my long-term portfolio. I have found two reasons why this firm is potentially a good addition. Let’s take a closer look.

Strong historical results

Between the 2017 and 2021 calendar years, the firm’s results have mostly shown consistent growth. Total revenue, for instance, has grown from $22bn to $37bn. Furthermore, net cash flow from operating activities has increased from $3.5bn to $5.9bn.

Both of these figures are encouraging for me as a potential investor. It’s particularly heartening to see net cash flows increase, because this allows the company both to invest in research and development and address its debt. The debt pile is not insignificant and currently stands at around $32bn. It should be noted, however that past performance is not necessarily indicative of future performance.

On the flip side, reported operating profit declined over the same period from $3.6bn to $1bn. What explains this fall? Much of this is due to AstraZeneca’s July 2021 takeover of Alexion Pharmaceuticals. This deal was reported to be worth somewhere in the region of $39bn.

So, while profits took a hit in the short term, I’m hoping that this takeover will enhance the company’s capabilities and range of products in the coming years.

What’s more, the business paid a dividend of $2.87 per share and hopes to increase this to $2.90 in future. While I’m looking at this company for long-term growth, it may also be a decent income source.

Active drug development

Recently, the firm has made solid progress on a number of treatments. Enhurtu, a breast cancer drug, performed well during a Phase 3 trial. In February 2022, the company noted that the drug provided a “clinically meaningful improvement” in survival when compared with chemotherapy.

Furthermore, the business stated in March 2022 that it had struck a collaboration agreement with biopharmaceutical company Neurimmune. This will allow AstraZeneca subsidiary Alexion to develop and manufacture NI006, a treatment for conditions leading to heart failure. This treatment is currently at the Phase 1b stage.

Finally, the firm gained full approval in the US for Lynparza, a treatment for high-risk early stage breast cancer, on 14 March. This tells me that the company is active in research and development, as one might expect of a pharmaceutical business. It’s also progressing more generally with a number of treatments well on the way through the approval process.

Overall, AstraZeneca has mostly strong historical results and is manufacturing and testing a number of life-changing treatments. I will be buying shares in this company without delay.   

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Andrew Woods has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Black father and two young daughters dancing at home
Investing Articles

1 FTSE 250 stock I own, and 1 I’d love to buy

Our writer explains why she’s eyeing up this FTSE 250 growth phenomenon, and may buy more shares in this property…

Read more »

View of Tower Bridge in Autumn
Investing Articles

The FTSE 100 is closing in on 8,000 points! Here’s what I’m buying before it’s too late!

As the FTSE 100 keeps gaining momentum, this Fool is on the lookout for bargains. Here's one stock he'd willingly…

Read more »

Investing Articles

3 ideas to help investors aim for a million-pound Stocks & Shares ISA

The UK has a growing number of Stocks and Shares ISA millionaires, and this plan may be one of the…

Read more »

Illustration of flames over a black background
Investing Articles

2 red-hot UK growth stocks to consider buying in April

These two growth stocks are performing well, but can they continue to deliver for investors through 2024 and beyond?

Read more »

Charticle

Is JD Sports Fashion one of the FTSE 100’s best value stocks? Here’s what the charts say!

The JD Sports Fashion share price remains a wild ride during the first quarter. Could it be one of the…

Read more »

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »